Journal of Gastrointestinal Surgery

, Volume 13, Issue 7, pp 1233–1237 | Cite as

Factors Influencing Lymph Node Recovery from the Operative Specimen after Gastrectomy for Gastric Adenocarcinoma

  • Scott J. Schoenleber
  • Thomas Schnelldorfer
  • Christina M. Wood
  • Rui Qin
  • Michael G. Sarr
  • John H. Donohue
Original Article



Regional lymph node metastases are an important predictor of survival for patients with resectable adenocarcinoma of the stomach. Currently, the number of lymph nodes examined is frequently less than requirements for accurate staging. Clinical factors associated with lymph node recovery are understood poorly.


We performed a retrospective chart review of 99 consecutive patients who underwent gastrectomy for gastric adenocarcinoma distal to the gastroesophageal junction to determine clinical variables associated lymph node recovery.


Ninety-nine patients underwent gastrectomy for gastric adenocarcinoma at our two hospitals. More than 15 lymph nodes were examined in 64% of specimens. Univariate analysis showed an association between the number of lymph nodes recovered and the number of positive nodes, lymphadenectomy extent, hospital, surgeon, and pathology technician (p < 0.001). Multivariate analysis identified the pathology technician as the most important healthcare-related variable contributing to the variation of lymph node recovery, using fixed- (p < 0.001) and random-effects models.


This study suggests that the pathology technician is an important healthcare-related factor influencing lymph node recovery after gastrectomy. In identifying potential areas benefiting from a systems improvements approach, focus on the technical aspects of specimen processing may be of benefit in maximizing the number of lymph nodes recovered.


Gastric cancer Lymph nodes Human factors Neoplasm staging 


  1. 1.
    Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228:449–461. doi:10.1097/00000658-199810000-00002.PubMedCrossRefGoogle Scholar
  2. 2.
    Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol 2005;23:7114–7124. doi:10.1200/JCO.2005.14.621.PubMedCrossRefGoogle Scholar
  3. 3.
    Bouvier AM, Haas O, Piard F, Roignot P, Bonithon-Kopp C, Faivre J. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002;94:2862–2866. doi:10.1002/cncr.10550.PubMedCrossRefGoogle Scholar
  4. 4.
    Ichikura T, Ogawa T, Chochi K, Kawabata T, Sugasawa H, Mochizuki H. Minimum number of lymph nodes that should be examined for the International Union Against Cancer/American Joint Committee on Cancer TNM classification of gastric carcinoma. World J Surg 2003;27:330–333. doi:10.1007/s00268-002-6730-9.PubMedCrossRefGoogle Scholar
  5. 5.
    Sobin LH, Wittekind C. TNM classification of malignant tumours, sixth edition. New York: Wiley-Liss, 2002.Google Scholar
  6. 6.
    Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC cancer staging manual, sixth edition. New York: Springer, 2002.Google Scholar
  7. 7.
    Reid-Lombardo KM, Gay G, Patel-Parekh L, Ajani JA, Donohue JH, Gastric Patient Care Evaluation Group from the Commission on Cancer. Treatment of gastric adenocarcinoma may differ among hospital types in the United States, a report from the National Cancer Data Base. J Gastrointest Surg 2007;11:410–419. doi:10.1007/s11605-006-0040-8.PubMedCrossRefGoogle Scholar
  8. 8.
    Baxter NN, Tuttle TM. Inadequacy of lymph node staging in gastric cancer patients: a population-based study. Ann Surg Oncol 2005;12:981–987. doi:10.1245/ASO.2005.03.008.PubMedCrossRefGoogle Scholar
  9. 9.
    Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer 2006;107:2143–2151. doi:10.1002/cncr.22229.PubMedCrossRefGoogle Scholar
  10. 10.
    Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? What are the suggestions? Crit Rev Oncol Hematol 2001;40:77–94. doi:10.1016/S1040-8428(00)00131-1.PubMedCrossRefGoogle Scholar
  11. 11.
    Candela FC, Urmacher C, Brennan MF. Comparison of the conventional method of lymph node staging with a comprehensive fat-clearing method for gastric adenocarcinoma. Cancer 1990;66:1828–1832. doi:10.1002/1097-0142(19901015)66:8<1828::AID-CNCR2820660830>3.0.CO;2-Z.PubMedCrossRefGoogle Scholar
  12. 12.
    Koren R, Kyzer S, Levin I, Klein B, Halpern M, Rath-Wolfson L, Paz A, Melloul MM, Mishali M, Gal R. Lymph node revealing solution: a new method for lymph node sampling: results in gastric adenocarcinoma. Oncol Rep 1997;5:341–344.Google Scholar
  13. 13.
    Bembenek A, Gretschel S, Schlag PM. Sentinel lymph node biopsy for gastrointestinal cancers. J Surg Oncol 2007;96:342–352. doi:10.1002/jso.20863.PubMedCrossRefGoogle Scholar
  14. 14.
    Gretschel S, Bembenek A, Hunerbein M, Dresel S, Schneider W, Schlag PM. Efficacy of different technical procedures for sentinel lymph node biopsy in gastric cancer staging. Ann Surg Oncol 2007;14:2028–2035. doi:10.1245/s10434-007-9367-y.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2009

Authors and Affiliations

  • Scott J. Schoenleber
    • 1
  • Thomas Schnelldorfer
    • 1
  • Christina M. Wood
    • 2
  • Rui Qin
    • 2
  • Michael G. Sarr
    • 1
  • John H. Donohue
    • 1
  1. 1.Division of Gastroenterologic and General SurgeryMayo ClinicRochesterUSA
  2. 2.Division of BiostatisticsMayo ClinicRochesterUSA

Personalised recommendations